Company / Assets per Share
Viridian Therapeutics, Inc.\DE Assets per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Assets per Share
$9.17
FY2024
5-year range
$9.17 / $17.09
FY2020-FY2024
Trend
-16.4%
vs FY2023
Sector context
#105 of 210
Health Care
What the data says
At $9.17, Viridian Therapeutics, Inc.\DE's assets per share ranks #105 of 210 in the Health Care sector. Assets per Share has declined for 4 consecutive years, from $36.90 in FY2020 to $9.17 in FY2024.
Based on SEC 10-K filings.
9.17 in FY2024 with a 5-year CAGR of -8.7%.
Declined from $13.56 to $9.17 over the past 2 years.
Health Care sector context is included.
Assets per Share over time
Growth rates
- 3-Year CAGR
- -18.8%
- 5-Year CAGR
- -8.7%
- 10-Year CAGR
- -
Sector benchmark
#105 of 210 in Health CareTop 50% of 210This company $9.17 Sector average $353.15
▼
-97.4% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's assets per share has declined for 4 consecutive years.
- In FY2024, assets per share decreased 16.4% year-over-year.
- Ranks #105 out of 210 companies in the Health Care sector.
- Peak assets per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Assets per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $9.17 | -16.4% |
| FY2023 | $10.96 | -19.2% |
| FY2022 | $13.56 | -20.7% |
| FY2021 | $17.09 | -53.7% |
| FY2020 | $36.90 | +154.7% |
| FY2019 | $14.49 | +548.2% |
| FY2018 | $2.23 | -96.4% |
| FY2017 | $62.95 | +80.3% |
| FY2016 | $34.92 | +923.8% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026